Incyte 2014 Annual Report
to Stockholders
Jakafi® (ruxolitinib)
Prescribing Information

is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology.

Baricitinib Superior to Methotrexate in Reducing Signs and Symptoms in Pivotal Phase 3 Study in Patients with Rheumatoid Arthritis
MPN Awareness Day Raises Awareness and Support for the Nearly 300,000 People in the United States Affected by Rare Blood Cancers
Incyte Announces Global License Agreement with Jiangsu Hengrui Medicine for SHR-1210, an Investigational Anti-PD-1 Monoclonal Antibody
Jakafi® (ruxolitinib)
Connecting to Access, Reimbursement, Education and Support
To learn more, click here